Did You Know?
MBBP has had a presence at CIC-Cambridge from its earliest days - 2004 to be exact.
We understand the complexities unique to the medical device technology space, and the highly competitive business environment in which medical device companies operate. Our work includes:
- Understanding and solving issues that are unique to the medical device arena;
- Serving as outside general counsel;
- Supporting in-house counsel through various stages of the life cycle of a company’s products and services.
Working with clients across a wide range of technical fields, including bioinformatics, biosensors, flow cytometry, mass spectrometry, fluidics, microarray technology, surgical instruments, drug delivery devices, organ transplant and maintenance systems, vascular grafts, intraluminal devices, orthopedic devices and instruments, biocompatible coatings and devices, imaging technologies, software implementations in the healthcare industry, mechanical and electrical devices with medical applications, and the like.
We regularly counsel our medical device clients in the areas of:
- Intellectual property
- Corporate governance and corporate finance
- Market regulation
- Legislative and government regulations
- Executive compensation
- International trade
- Building and managing an international patent portfolio for a platform technology of a medical device company leading up to its acquisition for almost $700 million.
- Leveraging a provisional application on a medical aesthetics technology into a worldwide patent portfolio protecting valuable market share, which was later purchased for a multi-million dollar valuation by a competitor.
- Direct Dial
- Finding Safe Harbor:
Protections from Infringement for Using Patented Inventions During the Regulatory Approval Process
November 21, 2017
- 2015 M&A Deals
A sampling of the year's M&A transactions
March 31, 2016
- Life Sciences Vector - Fall 2015
November 30, 2015
- U.S. Introduction to the Hague System
November 30, 2015
- Special Contractual and
Intellectual Property Rights Considerations
Sponsored Research Agreements, University and Government Licensing, and Clinical Trial Agreements
January 13, 2003